ImmunityBio, Inc. (IBRX)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
8.05 USD
-0.35
(-4.167%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 8.07 +0.02 (0.248%) ⇧ (Aug. 28, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:34 a.m. EDT
The immediate outlook is defined by a binary event risk rather than a steady trend. While the stock has recently rallied nearly 250%, the underlying business remains in a precarious position with negative earnings, negative free cash flow, and a balance sheet where debt significantly outweighs cash. The market is pricing in a 'lottery ticket' scenario where a positive clinical trial result could trigger the speculative call buying seen in the options chain, pushing the price toward the $10-$13 range. However, the lack of a dividend and the deteriorating fundamentals mean there is no safety net if the next data readout is underwhelming. The recent price action is driven entirely by momentum and anticipation of upcoming data, not by sustainable operational improvements. For investors, this is a high-risk speculation on a specific catalyst, not a long-term investment in a growing company. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.068748 |
| AutoETS | 0.071384 |
| AutoARIMA | 0.071384 |
| MSTL | 0.072419 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 1.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.046 |
| Excess Kurtosis | -0.42 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.165 |
| Market Cap | 8,531,682,304 |
| Forward P/E | -63.55 |
| Beta | 0.13 |
| Website | https://immunitybio.com |
As of Aug. 22, 2026, 2:34 a.m. EDT: Speculators are positioning for significant volatility rather than a clear directional bet. Call volume is heavily skewed toward out-of-the-money strikes (10.0 and 13.0) with massive open interest walls, suggesting a hope for a massive biotech catalyst spike. Conversely, put open interest is concentrated just below the current price (6.0 and 7.0), indicating a strong floor defense strategy against further downside. The implied volatility surface shows extreme spikes at deep out-of-the-money strikes, reflecting uncertainty about whether the stock will rally on clinical data or collapse on execution risks.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.5294118 |
| Address1 | 3,530 John Hopkins Court |
| All Time High | 45.42 |
| All Time Low | 0.93 |
| Ask | 39.9 |
| Ask Size | 5 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 8,490,200 |
| Average Daily Volume3 Month | 10,721,133 |
| Average Volume | 10,721,133 |
| Average Volume10Days | 8,490,200 |
| Beta | 0.125 |
| Bid | 8.06 |
| Bid Size | 1 |
| Board Risk | 9 |
| Book Value | -0.994 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.05 |
| Current Ratio | 5.721 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 8.3199 |
| Day Low | 7.945 |
| Display Name | ImmunityBio |
| Earnings Timestamp | 1,785,846,600 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | -235,298,000 |
| Ebitda Margins | -1.41924 |
| Enterprise To Ebitda | -39.965 |
| Enterprise To Revenue | 56.719 |
| Enterprise Value | 9,403,580,416 |
| Eps Current Year | -0.915 |
| Eps Forward | -0.12667 |
| Eps Trailing Twelve Months | -0.91 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.8122 |
| Fifty Day Average Change | 0.23780012 |
| Fifty Day Average Change Percent | 0.030439584 |
| Fifty Two Week Change Percent | 252.94118 |
| Fifty Two Week High | 12.43 |
| Fifty Two Week High Change | -4.38 |
| Fifty Two Week High Change Percent | -0.3523733 |
| Fifty Two Week Low | 1.95 |
| Fifty Two Week Low Change | 6.1000004 |
| Fifty Two Week Low Change Percent | 3.1282053 |
| Fifty Two Week Range | 1.95 - 12.43 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,438,090,200,000 |
| Float Shares | 406,637,981 |
| Forward Eps | -0.12667 |
| Forward P E | -63.55096 |
| Free Cashflow | -186,564,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 684 |
| Fullday Change | -0.349999 |
| Fullday Change Percent | -4.16666 |
| Fullday Price | 8.07 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.9934 |
| Gross Profits | 164,696,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.62167 |
| Held Percent Institutions | 0.19784 |
| Implied Shares Outstanding | 1,059,836,273 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California. |
| Long Name | ImmunityBio, Inc. |
| Market | us_market |
| Market Cap | 8,531,682,304 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_303022599 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -992,356,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,897,325,511 |
| Number Of Analyst Opinions | 4 |
| Open | 8.25 |
| Operating Cashflow | -281,137,984 |
| Operating Margins | -1.20408 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 844 696 5235 |
| Post Market Change | 0.019999504 |
| Post Market Change Percent | 0.24844104 |
| Post Market Price | 8.07 |
| Post Market Time | 1,787,961,553 |
| Previous Close | 8.4 |
| Price Eps Current Year | -8.797814 |
| Price Hint | 2 |
| Price To Book | -8.098592 |
| Price To Sales Trailing12 Months | 51.460155 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.355 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.349999 |
| Regular Market Change Percent | -4.16666 |
| Regular Market Day High | 8.3199 |
| Regular Market Day Low | 7.945 |
| Regular Market Day Range | 7.945 - 8.3199 |
| Regular Market Open | 8.25 |
| Regular Market Previous Close | 8.4 |
| Regular Market Price | 8.05 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 7,934,088 |
| Return On Assets | -0.30541 |
| Revenue Growth | 0.939 |
| Revenue Per Share | 0.165 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 1,059,836,273 |
| Shares Percent Shares Out | 0.120299995 |
| Shares Short | 127,495,672 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 134,395,641 |
| Short Name | ImmunityBio, Inc. |
| Short Percent Of Float | 0.318 |
| Short Ratio | 14.88 |
| Source Interval | 15 |
| State | CA |
| Symbol | IBRX |
| Target High Price | 15.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 12.75 |
| Target Median Price | 12.0 |
| Total Cash | 357,371,008 |
| Total Cash Per Share | 0.337 |
| Total Debt | 1,228,401,024 |
| Total Revenue | 165,792,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.91 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.42045 |
| Two Hundred Day Average Change | 1.62955 |
| Two Hundred Day Average Change Percent | 0.25380617 |
| Type Disp | Equity |
| Volume | 7,934,088 |
| Website | https://immunitybio.com |
| Zip | 92,121 |